Follow this preprint

Safety, Tolerability, and Immunogenicity of PIKA-Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine in Healthy Adults: Interim results of an open-label and randomised Phase 1 clinical trial

Yuan Liu, Lai Hock Tan, Nan Zhang, Yi Zhang, Zenaida Reynoso Mojares
doi: https://doi.org/10.1101/2022.11.20.22282565
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Back to top
Posted November 22, 2022.
Download PDF
Print/Save Options
Download PDFFull Text & In-line FiguresXML
Data/Code
Email
Safety, Tolerability, and Immunogenicity of PIKA-Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine in Healthy Adults: Interim results of an open-label and randomised Phase 1 clinical trial
Yuan Liu, Lai Hock Tan, Nan Zhang, Yi Zhang, Zenaida Reynoso Mojares
medRxiv 2022.11.20.22282565; doi: https://doi.org/10.1101/2022.11.20.22282565
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area

Reviews and Context

0

Comment

0

TRIP Peer Reviews

0

Community Reviews

0

Automated Services

0

Blogs/Media

0

Author Videos

You can now receive automatic notifications when a preprint is revised, withdrawn, commented on, peer reviewed, or published in a journal. Select the events you would like to follow below and click "Submit". To see all of the preprints you are currently following, please go to the medRxiv Alerts Page.

Sign In to Follow this Preprint

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.